PLK1 and colorectal carcinoma: GSEA showed that cell cycle‐related pathways, including mitotic spindle, E2F targets, and G2M checkpoint, were activated in oxaliplatin treatment but inhibited in volasertib and combination treatment (Figure 4A; Figure S4A, Supporting Information), suggesting that PLK1 is a key mediator of cell‐cycle deregulation in CRC.